|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is associated with hypertension in humans and animals, and studies suggest that cytochrome P4501A1 (Cyp1a1) induction and vascular dysfunction may contribute.
|
31115867 |
2019 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Cyp1a1-Ren-2 transgenic rats (iTGR) in which hypertension can be induced by natural xenobiotic indole-3 carbinol (I3C) added to the diet.
|
31037948 |
2019 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Hence, this study does not support the idea that microglial activation or BBB disruption contribute to the onset of angiotensin II-dependent hypertension in Cyp1a1-Ren2 rats, although BBB disruption might contribute to the progression from the early onset to well-established hypertension.
|
29500668 |
2018 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Prorenin independently causes hypertension and renal and cardiac fibrosis in cyp1a1-prorenin transgenic rats.
|
29848510 |
2018 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Logistic regression was performed to investigate the association of smoking and selected susceptibility variants in the LT pathway including ALOX5AP, LTA4H, LTC4S, PON1, and LTA as well as CYP1A1 on CAD risk while controlling for age, gender, BMI, family history, diabetes, hyperlipidemia, and hypertension.
|
25902778 |
2015 |
|
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genetic variations in CYP1A1 and CYP1B1 and the serum levels of 25(OH)D showed synergistic effect on BP, especially in individuals currently in treatment for hypertension.
|
25304467 |
2015 |
|
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The SNPs in CYP1A1-ULK3, HFE and SH2B3 were significantly associated with BP and/or HTN.
|
25231511 |
2015 |
|
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Administration of quercetin inhibited the development of DMBA-induced HBP carcinomas by impairing CYP-mediated ROS production via downregulation of the expression of CYP1A1 and CYP1B1, and upregulation of antioxidant defences.
|
22044346 |
2012 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
CTD_human |
Elevated blood pressure in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids.
|
22995157 |
2012 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Such increased urinary angiotensinogen excretion may contribute to augmented intrarenal ANG II levels and, thereby, to the increased blood pressure in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.
|
20724906 |
2010 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
CTD_human |
Because TCDD induces cytochrome P4501A1 (CYP1A1) and CYP1A1 can increase ROS, we tested the hypothesis that TCDD-induced endothelial dysfunction and hypertension are mediated by CYP1A1.
|
20634294 |
2010 |
|
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We genotyped 32 patients with hypertension for three CYP1A1 polymorphisms, and individuals with or without history of previous stroke were compared.
|
15185560 |
2004 |
|
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To explore this, we investigated interactive effects between smoking and the CYP1A1 MspI polymorphism on coronary artery disease (CAD), diabetes and hypertension in 701 patients (aged < or =65 years) consecutively referred to Eastern Heart Clinic for angiographic investigation.
|
11996959 |
2002 |